Search

Your search keyword '"Postadzhiyan A"' showing total 6 results
Start Over Author "Postadzhiyan A" Publisher elsevier ireland ltd
6 results on '"Postadzhiyan A"'

1. 2019 ESC/EAS Guidelines for the management of dyslipidaemias

Author

Mach, F., Baigent, C., Catapano, A.L., Koskinas, K.C., Casula, M., Badimon, L., Chapman, M.J., Backer, G.G. de, Delgado, V., Ference, B.A., Graham, I.M., Halliday, A., Landmesser, U., Mihaylova, B., Pedersen, T.R., Riccardi, G., Richter, D.J., Sabatine, M.S., Taskinen, M.R., Tokgozoglu, L., Wiklund, O., Nibouche, D., Zelveian, P.H., Siostrzonek, P., Najafov, R., Borne, P. van de, Pojskic, B., Postadzhiyan, A., Kypris, L., Spinar, J., Larsen, M.L., Eldin, H.S., Viigimaa, M., Strandberg, T.E., Ferrieres, J., Agladze, R., Laufs, U., Rallidis, L., Bajnok, L., Gudjonsson, T., Maher, V., Henkin, Y., Gulizia, M.M., Mussagaliyeva, A., Bajraktari, G., Kerimkulova, A., Latkovskis, G., Hamoui, O., Slapikas, R., Visser, L., Dingli, P., Ivanov, V., Boskovic, A., Nazzi, M., Visseren, F., Mitevska, I., Retterstol, K., Jankowski, P., Fontes-Carvalho, R., Gaita, D., Ezhov, M., Foscoli, M., Giga, V., Pella, D., Fras, Z., Isla, L.P. de, Hagstrom, E., Lehmann, R., Abid, L., Ozdogan, O., Mitchenko, O., Patel, R.S., Windecker, S., Aboyans, V., Collet, J.P., Dean, V., Fitzsimons, D., Gale, C.P., Grobbee, D., Halvorsen, S., Hindricks, G., Iung, B., Juni, P., Katus, H.A., Leclercq, C., Lettino, M., Lewis, B.S., Merkely, B., Mueller, C., Petersen, S., Petronio, A.S., Roffi, M., Shlyakhto, E., Simpson, I.A., Sousa-Uva, M., Touyz, R.M., Task Force Members, ESC Natl Cardiac Soc, and ESC Committee Practice Guidelines

Published
2020

2. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk

Author

François Mach, Colin Baigent, Alberico L. Catapano, Konstantinos C. Koskinas, Manuela Casula, Lina Badimon, M. John Chapman, Guy G. De Backer, Victoria Delgado, Brian A. Ference, Ian M. Graham, Alison Halliday, Ulf Landmesser, Borislava Mihaylova, Terje R. Pedersen, Gabriele Riccardi, Dimitrios J. Richter, Marc S. Sabatine, Marja-Riitta Taskinen, Lale Tokgozoglu, Olov Wiklund, Stephan Windecker, Victor Aboyans, Jean-Philippe Collet, Veronica Dean, Donna Fitzsimons, Chris P. Gale, Diederick Grobbee, Sigrun Halvorsen, Gerhard Hindricks, Bernard Iung, Peter Jüni, Hugo A. Katus, Christophe Leclercq, Maddalena Lettino, Basil S. Lewis, Bela Merkely, Christian Mueller, Steffen Petersen, Anna Sonia Petronio, Marco Roffi, Evgeny Shlyakhto, Iain A. Simpson, Miguel Sousa-Uva, Rhian M. Touyz, Djamaleddine Nibouche, Parounak H. Zelveian, Peter Siostrzonek, Ruslan Najafov, Philippe van de Borne, Belma Pojskic, Arman Postadzhiyan, Lambros Kypris, Jindřich Špinar, Mogens Lytken Larsen, Hesham Salah Eldin, Margus Viigimaa, Timo E. Strandberg, Jean Ferrières, Rusudan Agladze, Ulrich Laufs, Loukianos Rallidis, László Bajnok, Thorbjörn Gudjónsson, Vincent Maher, Yaakov Henkin, Michele Massimo Gulizia, Aisulu Mussagaliyeva, Gani Bajraktari, Alina Kerimkulova, Gustavs Latkovskis, Omar Hamoui, Rimvydas Slapikas, Laurent Visser, Philip Dingli, Victoria Ivanov, Aneta Boskovic, Mbarek Nazzi, Frank Visseren, Irena Mitevska, Kjetil Retterstøl, Piotr Jankowski, Ricardo Fontes-Carvalho, Dan Gaita, Marat Ezhov, Marina Foscoli, Vojislav Giga, Daniel Pella, Zlatko Fras, Leopoldo Perez de Isla, Emil Hagström, Roger Lehmann, Leila Abid, Oner Ozdogan, Olena Mitchenko, Riyaz S. Patel, HUS Heart and Lung Center, Clinicum, CAMM - Research Program for Clinical and Molecular Metabolism, Research Programs Unit, and University of Helsinki

Subjects
Male, CHRONIC KIDNEY-DISEASE, Very low-density lipoprotein, Apolipoprotein B, Lipoprotein remnants, 030204 cardiovascular system & hematology, INTIMA-MEDIA THICKNESS, chemistry.chemical_compound, 0302 clinical medicine, Risk Factors, 030212 general & internal medicine, High-density lipoproteins, HIGH-DOSE ATORVASTATIN, Hypolipidemic Agents, ALL-CAUSE MORTALITY, biology, Treatment (drugs), Lipoprotein(a), Middle Aged, Lipids, C-REACTIVE PROTEIN, 3. Good health, Treatment (adherence), Treatment Outcome, Cholesterol, DENSITY-LIPOPROTEIN CHOLESTEROL, Cardiovascular Diseases, Drug Therapy, Combination, Female, Low-density lipoproteins, Cardiology and Cardiovascular Medicine, Familial hypercholesterolaemia, Adult, medicine.medical_specialty, Consensus, Very low-density lipoproteins, TYPE-2 DIABETES-MELLITUS, Guidelines, Total cardiovascular risk, Risk Assessment, STATIN-TREATED PATIENTS, Treatment (lifestyle), 03 medical and health sciences, Internal medicine, Journal Article, medicine, Humans, CORONARY-HEART-DISEASE, HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA, Dyslipidaemias, Triglycerides, Aged, Dyslipidemias, business.industry, C-reactive protein, Type 2 Diabetes Mellitus, Endocrinology, chemistry, Intima-media thickness, 3121 General medicine, internal medicine and other clinical medicine, biology.protein, Lipid modification, business, Risk Reduction Behavior, Biomarkers
Abstract

Correction: Volume: 292 Pages: 160-162 DOI: 10.1016/j.atherosclerosis.2019.11.020 Published: JAN 2020

Published
2019

3. How to assess and manage cardiovascular risk associated with lipid alterations beyond LDL

Author

Averna, Maurizio, Stroes, Erik, Ogura, Masatsune, Postadzhiyan, Arman, Cercek, Miha, CALABRO', Paolo, Suppressa, Patrizia, Averna, M, Stroes, E, Averna, Maurizio, Stroes, Erik, Ogura, Masatsune, Postadzhiyan, Arman, Cercek, Miha, Calabro', Paolo, Suppressa, Patrizia, Vascular Medicine, Amsterdam Cardiovascular Sciences, and ACS - Atherosclerosis & ischemic syndromes

Subjects
medicine.medical_specialty, Apolipoprotein B, Type 2 diabetes, 030204 cardiovascular system & hematology, Risk Assessment, Triglyceride, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, High-density lipoprotein cholesterol, Risk Factors, Internal medicine, medicine, Internal Medicine, Humans, 030212 general & internal medicine, Atherogenic dyslipidaemia, Hypolipidemic Agents, biology, Cholesterol, business.industry, Disease Management, nutritional and metabolic diseases, General Medicine, Lipoprotein(a), Cholesterol, LDL, medicine.disease, Cardiovascular disease, Cardiovascular risk, Residual risk, Non-high-density lipoprotein cholesterol, Endocrinology, chemistry, Cardiovascular Diseases, Practice Guidelines as Topic, biology.protein, lipids (amino acids, peptides, and proteins), Metabolic syndrome, Hydroxymethylglutaryl-CoA Reductase Inhibitors, business, Risk assessment, Cardiology and Cardiovascular Medicine, Biomarkers, Lipoprotein
Abstract

Background and aims: The maintenance of clinically recommended levels of low-density lipoprotein cholesterol (LDL-C) through a statin therapy is a gold standard in the management of patients with dyslipidaemia and cardiovascular disease (CVD). However, even when LDL-C levels are at or below clinically recommended target levels, residual cardiovascular (CV) risk still remains. Therefore, assessing lipoproteins beyond LDL-C in managing CV risk is imperative. Methods: A working group of clinical experts have assessed the role of lipoproteins other than LDL-C in identifying the CV risk in patients with dyslipidaemia and CVD and in the management of atherogenic dyslipidaemia associated with a number of other diseases. The recommendations, in line with the European guidelines, are presented. Results: A thorough evaluation of clinical data by the expert working group resulted in recommendations to consider non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (apoB), remnant cholesterol and lipoprotein(a) (Lp[ a]) as biomarkers of residual CV risk in patients with CVD. Elevated Lp(a) levels were also suggested to be a causal factor. The experts highlighted the significance of nonHDL-C and triglycerides (TG) in atherogenic dyslipidaemia associated with type 2 diabetes, metabolic syndrome, chronic kidney disease (CKD) and familial combined hyperlipidaemia (FCH). The working group recommended combinatorial therapeutic approaches in high-risk patients, including agents impacting on TG and HDL-C levels. Conclusions: Evaluation of a lipoprotein landscape when LDL-C levels remain low strongly supports the role of non-HDL-C, Lp(a) and TGs in identifying patients with increased residual risk of CV and in selecting their treatment strategy. (C) 2017 Elsevier B.V. All rights reserved

Published
2017

4. Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

Author

Vallejo-Vaz, Antonio J., De Marco, Martina, Stevens, Christophe A. T., Akram, Asif, Freiberger, Tomas, Hovingh, G. Kees, Kastelein, John J. P., Mata, Pedro, Raal, Frederick J., Santos, Raul D., Soran, Handrean, Watts, Gerald F., Abifadel, Marianne, Aguilar-Salinas, Carlos A., Al-Khnifsawi, Mutaz, AlKindi, Fahad A., Alnouri, Fahad, Alonso, Rodrigo, Al-Rasadi, Khalid, Al-Sarraf, Ahmad, Ashavaid, Tester F., Binder, Christoph J., Bogsrud, Martin P., Bourbon, Mafalda, Bruckert, Eric, Chlebus, Krzysztof, Corral, Pablo, Descamps, Olivier, Durst, Ronen, Ezhov, Marat, Fras, Zlatko, Genest, Jacques, Groselj, Urh, Harada-Shiba, Mariko, Kayikcioglu, Meral, Lalic, Katarina, Lam, Carolyn S. P., Latkovskis, Gustavs, Laufs, Ulrich, Liberopoulos, Evangelos, Lin, Jie, Maher, Vincent, Majano, Nelson, Marais, A. David, Maerz, Winfried, Mirrakhimov, Erkin, Miserez, Andre R., Mitchenko, Olena, Nawawi, Hapizah M., Nordestgaard, Borge G., Paragh, Gyorgy, Petrulioniene, Zaneta, Pojskic, Belma, Postadzhiyan, Arman, Reda, Ashraf, Reiner, Zeljko, Sadoh, Wilson E., Sahebkar, Amirhossein, Shehab, Abdullah, Shek, Aleksander B., Stoll, Mario, Su, Ta-Chen, Subramaniam, Tavintharan, Susekov, Andrey V., Symeonides, Phivos, Tilney, Myra, Tomlinson, Brian, Thanh-Huong, Truong, Tselepis, Alexandros D., Tybjaerg-Hansenb, Anne, Vazquez-Cardenas, Alejandra, Viigimaa, Margus, Vohnout, Branislav, Widen, Elisabeth, Yamashita, Shizuya, Banach, Maciej, Gaita, Dan, Jiang, Lixin, Nilsson, Lennart, Santos, Lourdes E., Schunkert, Heribert, Tokgozoglu, Lale, Car, Josip, Catapano, Alberico L., Ray, Kausik K., Vallejo-Vaz, Antonio J., De Marco, Martina, Stevens, Christophe A. T., Akram, Asif, Freiberger, Tomas, Hovingh, G. Kees, Kastelein, John J. P., Mata, Pedro, Raal, Frederick J., Santos, Raul D., Soran, Handrean, Watts, Gerald F., Abifadel, Marianne, Aguilar-Salinas, Carlos A., Al-Khnifsawi, Mutaz, AlKindi, Fahad A., Alnouri, Fahad, Alonso, Rodrigo, Al-Rasadi, Khalid, Al-Sarraf, Ahmad, Ashavaid, Tester F., Binder, Christoph J., Bogsrud, Martin P., Bourbon, Mafalda, Bruckert, Eric, Chlebus, Krzysztof, Corral, Pablo, Descamps, Olivier, Durst, Ronen, Ezhov, Marat, Fras, Zlatko, Genest, Jacques, Groselj, Urh, Harada-Shiba, Mariko, Kayikcioglu, Meral, Lalic, Katarina, Lam, Carolyn S. P., Latkovskis, Gustavs, Laufs, Ulrich, Liberopoulos, Evangelos, Lin, Jie, Maher, Vincent, Majano, Nelson, Marais, A. David, Maerz, Winfried, Mirrakhimov, Erkin, Miserez, Andre R., Mitchenko, Olena, Nawawi, Hapizah M., Nordestgaard, Borge G., Paragh, Gyorgy, Petrulioniene, Zaneta, Pojskic, Belma, Postadzhiyan, Arman, Reda, Ashraf, Reiner, Zeljko, Sadoh, Wilson E., Sahebkar, Amirhossein, Shehab, Abdullah, Shek, Aleksander B., Stoll, Mario, Su, Ta-Chen, Subramaniam, Tavintharan, Susekov, Andrey V., Symeonides, Phivos, Tilney, Myra, Tomlinson, Brian, Thanh-Huong, Truong, Tselepis, Alexandros D., Tybjaerg-Hansenb, Anne, Vazquez-Cardenas, Alejandra, Viigimaa, Margus, Vohnout, Branislav, Widen, Elisabeth, Yamashita, Shizuya, Banach, Maciej, Gaita, Dan, Jiang, Lixin, Nilsson, Lennart, Santos, Lourdes E., Schunkert, Heribert, Tokgozoglu, Lale, Car, Josip, Catapano, Alberico L., and Ray, Kausik K.

Abstract

Background and aims: Management of familial hypercholesterolaemia (FH) may vary across different settings due to factors related to population characteristics, practice, resources and/or policies. We conducted a survey among the worldwide network of EAS FHSC Lead Investigators to provide an overview of FH status in different countries. Methods: Lead Investigators from countries formally involved in the EAS FHSC by mid-May 2018 were invited to provide a brief report on FH status in their countries, including available information, programmes, initiatives, and management. Results: 63 countries provided reports. Data on FH prevalence are lacking in most countries. Where available, data tend to align with recent estimates, suggesting a higher frequency than that traditionally considered. Low rates of FH detection are reported across all regions. National registries and education programmes to improve FH awareness/knowledge are a recognised priority, but funding is often lacking. In most countries, diagnosis primarily relies on the Dutch Lipid Clinics Network criteria. Although available in many countries, genetic testing is not widely implemented (frequent cost issues). There are only a few national official government programmes for FH. Under-treatment is an issue. FH therapy is not universally reimbursed. PCSK9-inhibitors are available in similar to 2/3 countries. Lipoprotein-apheresis is offered in similar to 60% countries, although access is limited. Conclusions: FH is a recognised public health concern. Management varies widely across countries, with overall suboptimal identification and under-treatment. Efforts and initiatives to improve FH knowledge and management are underway, including development of national registries, but support, particularly from health authorities, and better funding are greatly needed., Funding Agencies|Pfizer Independent Grant for Learning Change 2014 [16157823]; Amgen; MSD; Sanofi-Aventis

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results